Illumina has not yet disclosed the price it paid for the Canadian laboratory information management systems software developer.
Roche is buying Lumora's heat elution technology, which enables nucleic acid isolation in minutes, as opposed to hours.
GeneWeave's rule-in antibiotic susceptibility testing works where PCR doesn't and offers Roche the possibility of reshaping the microbiology laboratory.
Roche will make a $190 million upfront payment to GeneWeave and could pay an additional $235 million in product-related milestones.
The Belgium-based testing firm believes acquiring the university laboratory will strengthen its position in specialty clinical diagnostic testing.
The firms expanded their deal to develop a companion test for galeterone based on circulating tumor cell technology Qiagen has acquired from AdnaGen.
The firm landed Enzymatics' enzyme solutions unit in the December 2014 acquisition. It also plans to repurchase outstanding convertible notes.
Next month, Toxic Reports plans to fully launch the pathogen identification platform developed by PathoGenetix, which went belly up in the summer.
Crown is acquiring Molecular Response's existing PDX models and 8,000 viable human tumors for model development.
The firm said it plans to roll out the molecular diagnostic test, which is commercially available in Switzerland, to the rest of Europe through partnerships.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.